Cibus Stock
Cibus, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Craig Wichner
- Employees
- 118
- Market cap
- $101 M
- IPO
- 20/07/2017
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology…
Cibus stock: price history
1D
+2.3%
1W
-14.8%
1M
-12.6%
6M
-17.0%
YTD
-24.1%
1Y
-22.8%
2Y
-64.3%
5Y
-99.1%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~4% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Cibus
Analyst assessment of Cibus
PRICE TARGET LOW
US$10.50
CONSENSUS
US$11.50
MEDIAN
US$11.50
PRICE TARGET HIGH
US$12.50
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 25/03/2026
Cibus stock metrics
P/E
-0.8
P/B
6.84
EV/EBITDA
-1.97
RETURN ON EQUITY
-149.6%
NET MARGIN
-2,227.9%
DEBT/EQUITY
2.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
61.4%
FLOAT SHARES
46,890,185
AVG. DAILY VOLUME (30D)
119,634
Insider transactions (SEC)
Wichner Craig
Urban Thomas
Lehmann Jean-Pierre Jules
Prante Gerhard
Beetham Peter
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cibus stock
What does Cibus do?
Cibus, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Craig Wichner, the company employs around 118 people.
The IPO was on 20/07/2017; the stock trades on NASDAQ under the ticker CBUS.
What do analysts say about Cibus stock?
4 analysts rate the stock, the consensus is Buy (as of 25/03/2026).
The average price target is US$11.50, ranging from US$10.50 to US$12.50, with a median of US$11.50.
This is an external assessment, not a statement by Market Jury.
When does Cibus report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Cibus pay a dividend?
No, Cibus currently does not pay a dividend.
Which stocks are comparable to Cibus?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cibus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cibus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.